- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00070122
Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer
A Phase III Trial of Modified FOLFOX6 Versus CAPOX, With Bevacizumab (NSC-704865) or Placebo, as First-Line Therapy in Patients With Previously Untreated Advanced Colorectal Cancer
Descripción general del estudio
Estado
Condiciones
Descripción detallada
OBJECTIVES:
I. Compare overall survival in patients with locally advanced, metastatic, or recurrent colorectal cancer treated with fluorouracil, leucovorin calcium, oxaliplatin, and bevacizumab vs capecitabine, oxaliplatin, and bevacizumab.
II. Compare progression-free survival and time to treatment failure in patients treated with these regimens.
III. Compare the response of patients with measurable disease treated with these regimens.
IV.Compare toxicity rates of these regimens in these patients. V. Compare patient-reported functional status and convenience of therapy in patients treated with these regimens.
VI. Correlate germline polymorphisms of DNA repair (e.g., ERCC-1, XRCC1, GST-P1, XPD, and ribonucleotide reductase), target enzymes (e.g., thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase), angiogenesis (e.g., vascular endothelial growth factor), and growth factors (e.g., epithelial growth factor receptor) with survival, progression-free survival, and toxicity from chemotherapy in patients treated with these regimens.
VII. Correlate tumor mRNA expression levels of similar DNA repair enzymes as well as enzymes involved in angiogenesis with survival and progression-free survival in patients treated with these regimens.Correlate tumor mRNA expression levels of similar target enzymes before treatment with survival, progression-free survival, and toxicity in patients treated with these regimens.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to Zubrod performance status (0 or 1 vs 2) and prior adjuvant therapy (yes vs no). Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously over 46-48 hours beginning on day 1. Patients are further randomized to receive bevacizumab or placebo* IV over 30-90 minutes on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. NOTE: *As of 11/15/04, placebo is no longer part of treatment plan; all patients receive bevacizumab.
ARM II: Patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine on days 1-15. Patients are further randomized to receive bevacizumab or placebo* as in arm I. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. NOTE: *As of 11/15/04, placebo is no longer part of treatment plan; all patients receive bevacizumab.
Patients are followed every 3 months until disease progression. After disease progression, patients are followed every 6 months for 2 years and then annually for up to 4 years after study entry.
PROJECTED ACCRUAL: A total of 2,200 patients (1,100 per treatment arm) will be accrued for this study within 3 years.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Texas
-
San Antonio, Texas, Estados Unidos, 78245
- Southwest Oncology Group
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
Histologically or cytologically confirmed locally advanced, recurrent, or metastatic colorectal adenocarcinoma
- Not curable by surgery or amenable to radiotherapy with curative intent
Previously resected colorectal cancer with new evidence of metastasis does not require separate histologic or cytologic confirmation unless one of the following is true:
- More than 5 years has elapsed between primary surgery and development of metastatic disease
- Primary tumor was T1-T2, N0, M0
- Site of primary lesion must be or have been in the large bowel as determined by endoscopy, radiology, or surgery
- Measurable or evaluable disease
- No known brain or leptomeningeal disease
- Performance status - Zubrod 0-2
- No history of hemorrhagic or thrombotic disorders
- Absolute neutrophil count greater than 1,500/mm^3
- Platelet count greater than 100,000/mm^3
- Bilirubin no greater than 2.0 times upper limit of normal (ULN)
- SGOT no greater than 2.5 times ULN (5 times ULN for patients with liver involvement)
- Alkaline phosphatase no greater than 2.5 times ULN (5 times ULN for patients with liver involvement or 10 times ULN for patients with bone involvement)
- INR no greater than 1.5
- PTT no greater than ULN
- Creatinine no greater than 1.5 times ULN
- Creatinine clearance at least 50 mL/min
- Proteinuria less than 1+*
- Protein less than 500mg/24 hours*
No uncontrolled hypertension
- Hypertension must be well-controlled (i.e., less than 160/90) and on a stable regimen of antihypertensive therapy
- No unstable angina
- No symptomatic congestive heart failure
- No myocardial infarction within the past 6 months
- No serious uncontrolled cardiac arrhythmia
- No New York Heart Association class III or IV heart disease
- No symptomatic pulmonary fibrosis
- Not pregnant or nursing
- Fertile patients must use effective contraception
- No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer currently in complete remission
- No active or uncontrolled severe infection
No contraindication to oral medications (e.g., severe dysphagia)
- G-tubes or J-tubes allowed
- No peripheral neuropathy greater than grade 1
- No serious non-healing wound, ulcer, or bone fracture
- No significant traumatic injury within the past 28 days
- No other severe acute or chronic medical condition or laboratory abnormality that would preclude study participation
- No psychiatric condition that would preclude study participation
- No prior bevacizumab
- No prior oxaliplatin
No prior chemotherapy for advanced colorectal cancer
- Prior adjuvant therapy for resected stage II-III disease allowed provided at least 12 months have elapsed between completion of therapy and diagnosis of recurrent disease
- At least 28 days since prior radiotherapy and recovered
- See Disease Characteristics
- More than 28 days since prior major surgical procedure or open biopsy
- More than 7 days since prior fine needle aspiration or core biopsy
- No concurrent major surgery
- More than 10 days since prior full-dose aspirin (325 mg)
- No concurrent antiplatelet agents (e.g., dipyridamole, ticlopidine, clopidogrel, or cilostazol)
- No other concurrent investigational agents
No concurrent therapeutic anticoagulation
- Prophylactic anticoagulation of central venous lines allowed
- Low-dose prophylactic enoxaparin or heparin allowed
- No concurrent cimetidine
- No concurrent sorivudine or its related analogs (e.g., brivudine)
- No concurrent use of a cold cap or iced mouth rinses
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Arm I (oxaliplatin, leucovorin calcium, fluorouracil)
Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously over 46-48 hours beginning on day 1.
Patients are further randomized to receive bevacizumab or placebo* IV over 30-90 minutes on day 1.
Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
NOTE: *As of 11/15/04, placebo is no longer part of treatment plan; all patients receive bevacizumab.
|
Estudios correlativos
Dado IV
Otros nombres:
Dado IV
Otros nombres:
Dado IV
Otros nombres:
Dado IV
Otros nombres:
|
Experimental: Arm II (oxaliplatin, capecitabine)
Patients receive oxaliplatin IV over 2 hours on day 1and oral capecitabine on days 1-15.
Patients are further randomized to receive bevacizumab or placebo* as in arm I. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity NOTE: *As of 11/15/04, placebo is no longer part of treatment plan; all patients receive bevacizumab.
|
Estudios correlativos
Dado IV
Otros nombres:
Dado IV
Otros nombres:
Administrado oralmente
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Overall survival in patients with colorectal cancer treated with fluorouracil/leucovorin calcium and oxaliplatin with and without becavizumab versus those treated with capecitabine and oxaliplatin with our without bevacizumab
Periodo de tiempo: Up to 6 years
|
Will be analyzed primarily by the stratified Cox model.
|
Up to 6 years
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Time to treatment failure
Periodo de tiempo: Up to 6 years
|
Will be analyzed primarily by the Cox stratified model.
|
Up to 6 years
|
Progression-free survival
Periodo de tiempo: Up to 6 years
|
Will be analyzed primarily by the Cox stratified model.
|
Up to 6 years
|
Response (among patients with measurable disease)
Periodo de tiempo: Up to 6 years
|
Will be analyzed primarily by the Cox stratified model.
|
Up to 6 years
|
Treatment toxicities graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE 3.0)
Periodo de tiempo: Up to the time of progression
|
Up to the time of progression
|
|
Change in FACT-C TOI
Periodo de tiempo: Baseline to 25 weeks
|
The analysis for evaluating this change will be a comparison of the change score between the first and last assessment.
If cohort patterns for mean scores do not show signs of informative missing data, a mixed effects linear model approach will be used to measure change in FACT-C TOI scores.
|
Baseline to 25 weeks
|
Change in Chemotherapy Convenience and Satisfaction Questionnaire scores
Periodo de tiempo: Baseline to 25 weeks
|
Effect size will be used to compare the size of the difference in each arm.
|
Baseline to 25 weeks
|
Whether gene expression variables are predictive of survival and progression-free survival
Periodo de tiempo: Up to 6 years
|
Up to 6 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Charles Blanke, Southwest Oncology Group
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Digestivo
- Procesos Patológicos
- Neoplasias por tipo histológico
- Neoplasias
- Neoplasias por sitio
- Carcinoma
- Neoplasias Glandulares y Epiteliales
- Atributos de la enfermedad
- Neoplasias Gastrointestinales
- Neoplasias del Sistema Digestivo
- Enfermedades Gastrointestinales
- Enfermedades del Colon
- Enfermedades intestinales
- Neoplasias Intestinales
- Enfermedades Rectales
- Neoplasias colorrectales
- Reaparición
- Adenocarcinoma
- Neoplasias Rectales
- Neoplasias colónicas
- Efectos fisiológicos de las drogas
- Mecanismos moleculares de acción farmacológica
- Antimetabolitos, Antineoplásicos
- Antimetabolitos
- Agentes antineoplásicos
- Agentes inmunosupresores
- Factores inmunológicos
- Agentes Protectores
- Inhibidores de la angiogénesis
- Agentes moduladores de la angiogénesis
- Sustancias de crecimiento
- Inhibidores del crecimiento
- Micronutrientes
- Vitaminas
- Antídotos
- Complejo de vitamina B
- Anticuerpos
- Fluorouracilo
- Capecitabina
- Oxaliplatino
- Inmunoglobulinas
- Bevacizumab
- Leucovorina
- Levoleucovorina
- Anticuerpos Monoclonales
- Agentes antineoplásicos inmunológicos
Otros números de identificación del estudio
- NCI-2012-02556
- U10CA032102 (Subvención/contrato del NIH de EE. UU.)
- S0303
- CDR0000330000 (Identificador de registro: PDQ (Physician Data Query))
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cáncer de colon en estadio IV
-
City of Hope Medical CenterNational Cancer Institute (NCI)TerminadoTerapia con vacunas en el tratamiento de pacientes con cáncer colorrectal, de estómago o de páncreasCáncer de páncreas recurrente | Cáncer de páncreas en estadio III | Cáncer de páncreas en estadio IV | Cáncer de colon en estadio IV | Cáncer de recto en estadio IV | Cáncer gástrico en estadio IV | Cáncer de colon recurrente | Cáncer de recto recurrente | Cáncer gástrico recurrente | Cáncer de colon en... y otras condicionesEstados Unidos
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Aún no reclutandoAdenocarcinoma colorrectal metastásico | Adenocarcinoma de colon metastásico | Adenocarcinoma rectal metastásico | Cáncer de colon en estadio IV AJCC v8 | Cáncer colorrectal en estadio IV AJCC v8 | Cáncer de recto en estadio IV AJCC v8Estados Unidos
-
Ohio State University Comprehensive Cancer CenterTerminadoComparación de 2 fases de imágenes preoperatorias de TC y PET para el cáncer colorrectal metastásicoCáncer de colon recurrente | Cáncer de recto recurrente | Cáncer de vejiga en estadio IV A | Cáncer de recto en estadio IV A | Cáncer de colon en estadio IV B | Cáncer de recto en estadio IV BEstados Unidos
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)TerminadoCáncer de colon en estadio IV | Cáncer de recto en estadio IVEstados Unidos
-
City of Hope Medical CenterNational Cancer Institute (NCI)ReclutamientoAdenocarcinoma colorrectal metastásico | Adenocarcinoma de colon metastásico | Adenocarcinoma rectal metastásico | Cáncer de colon en estadio IV AJCC v8 | Cáncer colorrectal en estadio IV AJCC v8 | Cáncer de recto en estadio IV AJCC v8 | Carcinoma colorrectal estable microsatélite metastásicoEstados Unidos
-
Seoul National University HospitalNational Cancer Center, Korea; Chonbuk National University Hospital; Asan Medical... y otros colaboradoresTerminadoCáncer de pulmón en estadio IV | Cáncer de páncreas en estadio IV | Cáncer de mama en estadio IV | Tumor cerebral pediátrico | Cáncer de colon en estadio IV | Cáncer gástrico en estadio IV | Cáncer de hígado en estadio IV | Neoplasia hematológica maligna | Tumor sólido pediátrico | Linfoma pediátrico | Metastásico... y otras condicionesCorea, república de
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)TerminadoCáncer de colon en estadio IV | Cáncer de recto en estadio IV | Cáncer de colon recurrente | Cáncer de recto recurrenteEstados Unidos
-
University of Southern CaliforniaNovartisTerminadoCáncer de colon en estadio IV | Cáncer de recto en estadio IV | Cáncer de colon recurrente | Cáncer de recto recurrenteEstados Unidos
-
National Cancer Institute (NCI)TerminadoCáncer de colon en estadio IV | Cáncer de recto en estadio IV | Cáncer de colon recurrente | Cáncer de recto recurrenteEstados Unidos
-
National Cancer Institute (NCI)TerminadoCáncer de colon en estadio IV | Cáncer de recto en estadio IV | Cáncer de colon recurrente | Cáncer de recto recurrenteEstados Unidos
Ensayos clínicos sobre análisis de biomarcadores de laboratorio
-
ORIOL BESTARDTerminadoTrasplante de riñón | Infección por CMVEspaña, Bélgica
-
Vanderbilt University Medical Center4DMedicalTerminado
-
Central and North West London NHS Foundation TrustBritish HIV Association (BHIVA)Aún no reclutandoInfecciones por VIH | Hepatitis B
-
Johns Hopkins UniversityReclutamiento
-
University of MiamiActivo, no reclutando
-
Hvidovre University HospitalElsassFondenTerminadoAcidosis metabólica del recién nacidoDinamarca
-
Rio de Janeiro State UniversityCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Conselho Nacional... y otros colaboradoresTerminadoEnfermedades cardiovasculares | Deficiencia de vitamina D | Condiciones relacionadas con la menopausiaBrasil